Retatrutide Is Not Approved in Any Country. It Is Also for Sale in Most of Them

Retatrutide has not been approved by any regulator on earth. Eli Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, and a review takes time after that. No pharmacy anywhere can legally dispense it as a medicine today.

It is, nonetheless, extremely easy to buy. It has been for two years.

The usual response to this is a warning about counterfeits, which is fair and which we have covered in our reporting on what testing actually finds in grey-market vials. But counterfeiting is not the most interesting problem here, because it assumes the danger is getting the wrong molecule. Assume for a moment you get the right one. That is when this becomes genuinely instructive.

Why is an unapproved drug so easy to buy?

Through a phrase doing enormous legal work: research use only.

Sellers label the vial as a research chemical, not for human consumption, and that sentence is what keeps them outside the medicines framework. It is a jurisdictional shield, not a description of the product and certainly not a quality standard. Nobody buying retatrutide from a website is conducting research, and everybody in the transaction knows it.

The result is a market with the vocabulary of pharmacology and none of its obligations. No batch release testing you can audit. No stability data for a peptide that has probably crossed several borders at uncertain temperatures. No adverse event reporting, so nothing that goes wrong for you ever teaches anybody anything. No recall mechanism, because there is nobody to issue one.

But it passed phase 3. Is that not good enough?

This is the argument that persuades intelligent people, and it is the one worth taking apart properly.

The trials were genuinely impressive. TRIUMPH-1 produced around 30.3 per cent weight loss at 104 weeks. TRIUMPH-3, in 1,949 adults with severe obesity and established cardiovascular disease, produced 22.6 per cent at the top dose. Those are the largest figures any obesity drug has posted.

Now look at what else those trials contained, because the drug was never the whole intervention.

• A titration schedule. Participants did not start at 12 mg. Doses were escalated slowly and deliberately, because the gastrointestinal effects are dose-related and starting high is how you make someone violently ill.
• Clinicians who could stop it. In TRIUMPH-3, between 9.8 and 13.5 per cent of participants discontinued because of adverse events, against 4.8 per cent on placebo. Roughly one in eight people could not tolerate this drug with a medical team, a titration plan and someone to call.
• Monitoring for the things that do not hurt. The glucagon arm carries a heart rate rise, and there have been transient elevations in the liver enzyme ALT. Neither of those announces itself. You find them because somebody ordered the test.
• Exclusion criteria. Trials screen people out. A website does not ask whether you have a personal or family history of medullary thyroid carcinoma, pancreatitis, or an eating disorder.